Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risedronate once a week.

Ngaire J White1, Caroline M Perry

  • 1Adis International Inc., Yardley, Pennsylvania, 19067, USA. demail@adis.com

Treatments in Endocrinology
|June 29, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.

Drugs·2014
Same author

Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.

Drugs·2014
Same author

Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.

Drugs·2014
Same author

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.

Drugs·2013
Same author

Simeprevir: first global approval.

Drugs·2013
Same author

Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.

Paediatric drugs·2013
Same journal

The replacement of human insulin with insulin analogs: a survey conducted in france to determine current and recommended practice.

Treatments in endocrinology·2006
Same journal

Is there a rationale for insulin therapy in pre-diabetic individuals?

Treatments in endocrinology·2006
Same journal

Optimizing the benefits of bisphosphonates in osteoporosis : the importance of appropriate calcium intake.

Treatments in endocrinology·2006
Same journal

Is bio-identical hormone replacement therapy safer than traditional hormone replacement therapy?: a critical appraisal of cardiovascular risks in menopausal women.

Treatments in endocrinology·2006
Same journal

A review of transdermal hormonal contraception : focus on the ethinylestradiol/norelgestromin contraceptive patch.

Treatments in endocrinology·2006
Same journal

Anabolic Agents for Osteoporosis : What is Their Likely Place in Therapy?

Treatments in endocrinology·2006
See all related articles

Weekly risedronate (risedronic acid) 35mg is as effective as daily 5mg for postmenopausal osteoporosis, improving bone mineral density and reducing vertebral fractures with similar tolerability.

Area of Science:

  • Pharmacology
  • Bone Metabolism
  • Osteoporosis Treatment

Background:

  • Risedronate is a bisphosphonate used to treat postmenopausal osteoporosis.
  • Its long half-life supports less frequent dosing regimens.
  • Understanding the efficacy and safety of weekly dosing is crucial for patient adherence.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of once-weekly risedronate 35mg compared to once-daily risedronate 5mg in postmenopausal osteoporosis.
  • To assess the impact on bone mineral density (BMD) and vertebral fracture incidence.

Main Methods:

  • A randomized, double-blind, multicenter trial involving 1456 women with postmenopausal osteoporosis.
  • Comparison of risedronate 35mg once-weekly versus risedronate 5mg once-daily.

Related Experiment Videos

  • Assessment of BMD at the hip and lumbar spine, and historical analysis for vertebral fractures.

    • Main Results:

    • Once-weekly risedronate 35mg demonstrated comparable efficacy to once-daily 5mg in improving lumbar spine and hip BMD at 12 months.
    • Mean BMD increases were similar across groups, meeting non-inferiority criteria.
    • Historical analysis indicated a significant reduction in vertebral fractures with weekly risedronate compared to placebo.
    • Tolerability profiles, including upper gastrointestinal events, were similar between the weekly and daily regimens.

    Conclusions:

    • Once-weekly risedronate 35mg is a non-inferior alternative to daily 5mg for managing postmenopausal osteoporosis.
    • The convenience of weekly dosing may improve patient adherence.
    • Risedronate, in both weekly and daily forms, effectively modulates bone metabolism and reduces fracture risk.